In the present experiment, we examined the effects of OPB-3206, 3S-[4-(N-hydroxyamino)-2R-isobutylsuccinyl]amino-1-methoxy-3,4-dihydrocarbostyril, a novel metalloproteinase inhibitor, on the growth and metastasis of transplantable osteosarcomas (spontaneous osteosarcoma, selected lung metastatic lesions; S-SLM), which were previously established in rats. OPB-3206 inhibited the activities of interstitial collagenase, gelatinases A and B, and stromelysin in vitro. After oral administration to rats, its serum concentration peaked at 40 min and the drug was no longer detectable at 8 h. When OPB-3206 was orally administered at 0%, 0.1% and 0.4% in the diet for 4 weeks, starting 7 days after subcutaneous transplantation of osteosarcomas to male Fischer 344 rats, numbers of lung metastatic nodules were significantly reduced by the highest dose, while the growth of subcutaneous tumors was not affected. Zymographic analysis showed the presence of pro matrix metalloproteinase (proMMP)-2, proMMP-9 and MMP-9 activities in S-SLM. In animals fed 0.4% OPB-3206, the activity of proMMP-9 was increased, but that for MMP-9 had become undetectable. The results thus suggest that OPB-3206 selectively inhibits lung metastasis of rat transplantable osteosarcomas by inhibiting MMP-9 activation.
Key words: Rat transplantable osteosarcomas -Metalloproteinase inhibitor -Spontaneous metastasis -OPB-3206Osteosarcomas readily spread via the bloodstream to the lungs, resulting in metastases that make the prognosis poor after noncurative or even curative treatments. 1) To prevent the development of secondaries, it is therefore important to give optimal chemotherapeutic treatment. Previously, we established transplantable osteosarcomas with rapid growth and high lung metastatic potential after serial transplantation into the subcutaneous back space of syngeneic rats.2-7) They represent useful osteosarcoma models for testing novel anti-metastatic therapies.Expression and activation of matrix metalloproteinases (MMPs) appear to play important roles in metastatic processes, [8][9][10][11][12][13] such as local tumor expansion through adjacent normal tissues, invasion of blood vessels and lymphatics, and extravasation at distant sites. MMPs also appear to be involved in angiogenesis, mediating tissue remodeling and penetration of the extracellular matrix by new capillaries.13) An MMP inhibitor should, therefore, have the potential to inhibit both tumor growth and spread.OPB-3206, 3S-[4-(N-hydroxyamino)-2R-isobutylsuccinyl]amino-1-methoxy-3,4-dihydrocarbostyril, is a novel agent which was designed to be administered orally, and to inhibit MMP activity by binding reversibly to the zincbinding region of MMPs. In this study, we investigated the effects of orally administered OPB-3206 on tumor growth and spontaneous lung metastasis in our rat transplantable osteosarcoma model. We also explored the effects of OPB-3206 on mRNA levels of MMP-2, MMP-9. TIMP-1 and TIMP-2, and on the gelatinolytic activities of MMP-2 and MMP-9.
MATERIALS AND METHODSChemical OP...